NCT04579757 2025-05-08
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
Hutchmed
Instituto do Cancer do Estado de São Paulo
Eli Lilly and Company
H. Lee Moffitt Cancer Center and Research Institute